IGM Biosciences to Present at RBC Capital Markets Global Healthcare Conference 2022

IGM Biosciences, Inc.

MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on the creation and development of IgM antibodies, today announced that Fred Schwarzer, Chairman and CEO, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York City.

A live webcast of the event will be available on the “Events and Presentations” page of the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/ events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Based in Mountain View, Calif., IGM Biosciences is a clinical-stage biotechnology company focused on the creation and development of engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome barriers to protein manufacturing and engineering that have limited the therapeutic use of IgM antibodies. Through his efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for clinical indications where their inherent properties may offer advantages over IgG antibodies.

Contact
Slang Partners
David Pitts
212-600-1902
[email protected]